levocabastine   Click here for help

GtoPdb Ligand ID: 1586

Synonyms: levocobastine | Livostin®
Approved drug
levocabastine is an approved drug (FDA (1993))
Compound class: Synthetic organic
Comment: In addition to acting at the histamine H1 receptor, levocabastine is also a selective antagonist for the neurotensin receptor NTS2, and has been used to characterise the different receptor subtypes [5,5]. This ligand is represented on PubChem by CID 54385.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 64.33
Molecular weight 420.22
XLogP 5.03
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES N#CC1(CCC(CC1)N1CCC(C(C1)C)(C(=O)O)c1ccccc1)c1ccc(cc1)F
Isomeric SMILES N#C[C@@]1(CC[C@@H](CC1)N1CC[C@]([C@@H](C1)C)(C(=O)O)c1ccccc1)c1ccc(cc1)F
InChI InChI=1S/C26H29FN2O2/c1-19-17-29(16-15-26(19,24(30)31)21-5-3-2-4-6-21)23-11-13-25(18-28,14-12-23)20-7-9-22(27)10-8-20/h2-10,19,23H,11-17H2,1H3,(H,30,31)/t19-,23-,25-,26-/m1/s1
InChI Key ZCGOMHNNNFPNMX-KYTRFIICSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Botto JM, Chabry J, Sarret P, Vincent JP, Mazella J. (1998)
Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism.
Biochem Biophys Res Commun, 243 (2): 585-90. [PMID:9480852]
2. Chalon P, Vita N, Kaghad M, Guillemot M, Bonnin J, Delpech B, Le Fur G, Ferrara P, Caput D. (1996)
Molecular cloning of a levocabastine-sensitive neurotensin binding site.
FEBS Lett, 386 (2-3): 91-4. [PMID:8647296]
3. Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP. (1996)
Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain.
J Neurosci, 16 (18): 5613-20. [PMID:8795617]
4. Richard F, Barroso S, Martinez J, Labbé-Jullié C, Kitabgi P. (2001)
Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.
Mol Pharmacol, 60 (6): 1392-8. [PMID:11723247]
5. Schotte A, Leysen JE, Laduron PM. (1986)
Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain.
Naunyn Schmiedebergs Arch Pharmacol, 333 (4): 400-5. [PMID:3022160]